Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest UCB Stories

2010-06-15 07:30:00

BRUSSELS, June 15 /PRNewswire-FirstCall/ -- New data from a retrospective cohort study showed that up to three quarters of patients with Parkinson's disease (PD) developed gastrointestinal disorders (GID) that can have a substantial adverse effect on major PD-related clinical and health economic outcomes. These data were presented at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010). "The new retrospective cohort...

2010-06-14 10:30:00

ATLANTA, June 14 /PRNewswire/ -- Lt. Governor Casey Cagle today joined Georgia Bio, the Georgia Research Alliance, the Metro Atlanta Chamber and the Innovation Crescent business community in announcing the launch of the Georgia Bioscience Commercialization Center (GBCC), which will act as a start-up catalyst and resource center for bioscience entrepreneurs in Georgia. "The Georgia Bioscience Commercialization Center is a first of its kind initiative in Georgia, drawing on the expertise of...

2010-06-14 08:30:00

ATLANTA, June 14 /PRNewswire/ -- UCB today announced the availability of an oral solution formulation of Vimpat® (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older. Vimpat 10 mg/mL solution is now available in U.S. pharmacies. To view the multimedia assets associated with this release, please click: http://www.prnewswire.com/mnr/vimpat/34012/ Download a high resolution photograph...

2010-05-19 14:16:06

Improved treatment of severe epilepsy could reduce the overall cost of the condition, according to research presented at the annual meeting of the International Society of Pharmacoeconomic Outcomes Research (ISPOR) at the Hilton Atlanta in Atlanta, Georgia. According to the authors, the annual cost of non-drug treatment of epilepsy increases disproportionately with the severity of the disease, while antiepileptic drug (AED)-related costs remain stable regardless of disease severity. The...

2010-05-02 08:15:00

ATLANTA, May 2 /PRNewswire/ -- UCB announced today results of an open-label extension study, PRECiSE 4 (P4), of Cimzia® (certolizumab pegol; CZP) demonstrating that Cimzia provides sustained efficacy over four years in moderate to severe Crohn's Disease patients regardless of whether patients were previously treated with infliximab (IFX) or infliximab-naive. Cimzia is indicated for reducing the signs and symptoms of Crohn's Disease and maintaining clinical response in...

2010-04-14 07:30:00

ATLANTA, April 14 /PRNewswire/ -- Evidence of Neupro® (Rotigotine Transdermal System) improving motor as well as non-motor symptoms of Parkinson's disease was presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada. "The new data reported this week showed that treatment with rotigotine controlled early morning motor function and improved non-motor symptoms, as judged by the validated non-motor scale, in patients with Parkinson's disease...

2010-04-09 08:16:00

ATLANTA, April 9 /PRNewswire/ -- The antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) will be the subject of numerous studies and analyses at the 62nd annual American Academy of Neurology (AAN) meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17. To view the multimedia assets associated with this release, please click: http://www.prnewswire.com/mnr/vimpat/34012/ "The breadth and depth of Vimpat data being presented at AAN...

2010-04-08 07:30:00

ATLANTA, April 8 /PRNewswire/ -- Extensive new data on rotigotine will be presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada between April 10th and 17th, 2010. At a series of oral and poster presentations, leading international investigators will report the latest data on rotigotine in all stages of Parkinson's disease and in moderate to severe Restless Legs Syndrome (RLS). Oral presentations SP710 (5 year) Long-term Safety and Efficacy of Rotigotine...

2010-03-05 11:03:00

ATLANTA, March 5 /PRNewswire/ -- Applications are being accepted until March 19, 2010 for the UCB Rheumatoid Arthritis Family Scholarship. These scholarships are for rheumatoid arthritis patients or their immediate family members. Winners are awarded up to $10,000 to continue their studies at an accredited institution of higher education in the U.S. Requirements and an application can be found at http://www.reachbeyondra.com/scholarship. UCB awards more than 100 scholarships each year to...

2010-01-28 07:02:00

DALLAS, January 28 /PRNewswire/ -- Now in its 9th year, the ePharma Summit (http://www.epharmasummit.com), to be held this year at the Hyatt Regency at Penn's Landing, Philadelphia, PA ,continues to be the most innovative digital marketing event for the pharmaceutical sector. Year after year, hundreds of marketing professionals from leading pharmaceutical companies attend ePharma Summit for incomparable access to insider information, to optimize their brand strategy and perfect consumer...